Summarized by Daily Strand AI from peer-reviewed source
Prime editing is a highly precise genetic tool that allows scientists to rewrite DNA without making dangerous double-strand breaks in the genetic code. To do this, the system relies on a guide molecule made of RNA, which acts like a biological GPS to find the exact spot in the genome that needs fixing. However, these RNA guides are fragile and can break down inside cells before they finish the job. To protect them, scientists attach tiny stabilizing structures, known as motifs, to the end of the RNA guide.
To find the best possible stabilizers, researchers developed a new high-throughput testing system called PE-PRISM. This tool allowed them to rapidly screen 2,858 different RNA motifs inside human cells. Through multiple rounds of testing and optimization, the research team identified three engineered winners named tevo2.0, eHAV, and eSBRMV1-A.
When put to the test, these newly upgraded motifs completely outperformed the current standard stabilizer. In experiments designed to correct hundreds of disease-associated genetic mutations, the top new motifs proved more efficient than the older version over 90 percent of the time. The researchers successfully used these stabilized guides to correct mutations in human cells as well as inside the brains and livers of living mice.
Improving the efficiency of prime editing is a crucial step for turning this breakthrough technology into a reliable medical treatment. By making the RNA guides more stable, scientists can successfully correct a wider range of genetic diseases with a much higher success rate. The fact that these new motifs worked so well in the brains and livers of living mice suggests that the upgraded system is powerful enough to tackle complex diseases in whole organisms, rather than just isolated cells in a laboratory.
Despite these exciting results, the research is still in its early preclinical stages. Because the current experiments rely entirely on cellular and mouse models, the upgraded prime-editing system will require extensive testing and safety validation before it can be used in human clinical trials. Nevertheless, these protective RNA designs bring the medical field an important step closer to safe, highly efficient gene therapies.
Interested in Gene Therapy?
Newsletter
Never miss a breakthrough.
Join 10,000+ curious minds getting biotech stories distilled into plain language. Free, three times a week.